A method for creating a canine pharmacokinetic model for drug multimodality

Abstract

The invention relates to a method for creating an animal pharmacokinetic model of drug multi-peak phenomenon. Include the following steps: select at least 6 dogs, half male and half female, administer according to the dose, collect blood samples after administration, and ensure that at least 2 blood collection points are collected before the first peak at the time point of blood collection, near the highest value of each peak At least 3 blood collection points were collected, and at least 3 blood collection points were collected after the last peak; blood drug concentration was measured by liquid chromatography mass spectrometry; the fitting constant was calculated according to 5 types of dogs ( DM), The minimum value is the pharmacokinetic standard model class for the dog. This model can establish a standard model in the dog body, and correctly calculate the pharmacokinetic parameters of this type of drug, and obtain a reasonable dosage regimen. The pharmacokinetic parameters of the multimodal drug calculated by the generation software are too small, which causes the defect of excessive dosage in dogs.

Description

technical field [0001] The invention relates to a method for creating an animal pharmacokinetic model of drug multi-peak phenomenon. Background technique [0002] New drug research is an inevitable stage of drug development. Drugs can only enter the clinical drug research stage after laboratory pharmacological research and preclinical animal research, and finally become new drugs. Pharmacokinetic parameters have important implications for drug dosing in laboratory pharmacology studies and preclinical animal studies. The pharmacist draws a reasonable dosage plan according to the national regulations according to the pharmacokinetic parameters, and specifies the dosage and the number of administrations for each study animal. If the dosage is too high, it will cause toxic and side effects to the animals. If the dose is too low, the drug effect will not be produced, which will affect the evaluation of the therapeutic effect and safety of the drug. [0003] At this stage, DAS s...

AI Technical Summary

Problems solved by technology

However, for certain classes of drugs (such as flavonoids, anthraquinones, polyphenols, non-steroidal anti-inflammatory drugs), the plasma concentration-time curve of these drugs has multiple peaks

The pharmacokinetic parameters calculated by commonly used software are too small, especially the half-life is too small. If the dosage plan designed according to the pharmacokinetic parameters is too large and the number of times of taking the medicine is too high, it will cause toxic and side effects and affect the drug in the animal pharmacological model. The evaluation of therapeutic effect and safety, which in turn affects the results of preclinical pharmacological studies and pharmacokinetic studies of drugs

Images